Thioester cationic lipids
Disclosed are cationic lipids which are compounds of Formula (I), (II), (III), (IV), (V), or (VI). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
1. A cationic lipid having the following structure:
wherein R is
2. A composition comprising an mRNA encoding a peptide or a polypeptide, encapsulated within a liposome, wherein the liposome comprises one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids, wherein the one or more cationic lipids has a structure according to claim 1 .
3. The composition of claim 2 , comprising an mRNA encoding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, ornithine transcarbamylase (OTC) protein, or an antigen from an infectious agent.
4. A composition comprising a nucleic acid encapsulated within a liposome, wherein the liposome comprises a cationic lipid according to claim 1 .
5. The composition of claim 4 , further comprising one or more lipids selected from the group consisting of one or more cationic lipids, one or more non-cationic lipids, and one or more PEG-modified lipids.
6. The composition of claim 4 , wherein the nucleic acid is an mRNA encoding a peptide or polypeptide.
7. The composition of claim 6 , wherein the mRNA encodes cystic fibrosis transmembrane conductance regulator (CFTR) protein.
8. The composition of claim 6 , wherein the mRNA encodes ornithine transcarbamylase (OTC) protein.
9. A vaccine comprising the composition of claim 6 .
10. The composition of claim 6 , wherein the mRNA encodes an antigen.
11. The composition of claim 10 , wherein the antigen is from an infectious agent.
12. The composition of claim 2 , formulated for intravenous (IV) administration, intramuscular (IM) administration, or inhaled administration that is nebulization.
13. The cationic lipid of claim 1 , having the following structure:
wherein R is
14. A method of delivering a cystic fibrosis transmembrane conductance regulator (CFTR) protein to the lung of a subject, said method comprising administering to the subject the composition of claim 7 .
15. A method of delivering an ornithine transcarbamylase (OTC) protein to the liver of a subject, said method comprising administering to the subject the composition of claim 8 .
16. The vaccine of claim 9 , wherein the mRNA encodes an antigen.
17. The vaccine of claim 16 , wherein the antigen is from an infectious agent.